Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 250 |
| Active Pipeline (Recruiting Now) | 99 (57) |
| Completed vs Stopped Early | 22 / 12 (4.8%) |
| Median Closed Actual Enrollment | 33 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Peking Union Medical College Hospital | Beijing, Beijing Municipality | 158 |
| Beijing Hospital | Beijing, Beijing Municipality | 3 |
| Peking University First Hospital | Beijing, Beijing Municipality | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06037889 | Efficacy and Safety of Tirofiban for Patients With BAD (BRANT) | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Peking Union Medical College Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.